Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1
Background Dolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450 3A (CYP3A). Therefore, we focused on UGT1A1 gene polymorphisms (*6 and *28) in Japanese individuals infected with human immunodeficiency virus (HIV)-1...
Saved in:
| Published in | BMC infectious diseases Vol. 17; no. 1; pp. 622 - 8 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
16.09.2017
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1471-2334 1471-2334 |
| DOI | 10.1186/s12879-017-2717-x |
Cover
| Abstract | Background
Dolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450 3A (CYP3A). Therefore, we focused on
UGT1A1
gene polymorphisms (*6 and *28) in Japanese individuals infected with human immunodeficiency virus (HIV)-1 to examine the relationship between their plasma trough concentration of DTG and gene polymorphisms. Recently, neuropsychiatric adverse events (NP-AEs) after the use of DTG have become a concern, so the association between
UGT1A1
gene polymorphisms and selected NP-AEs was also investigated.
Methods
The study subjects were 107 Japanese patients with HIV-1 infections who were receiving DTG. Five symptoms (dizziness, headache, insomnia, restlessness, and anxiety) were selected as NP-AEs. The subjects were classified by their
UGT1A1
gene polymorphisms for the group comparison of DTG trough concentration and the presence or absence of NP-AEs.
Results
The subjects consisted of eight (7%) *6 homozygotes, three (3%)
*
28 homozygotes, four (4%) for *6/
*
28 compound heterozygotes, 23 (21%) *6 heterozygotes, 18 (17%)
*
28 heterozygotes, and 51 (48%) patients carrying the normal allele. The plasma DTG trough concentration of the *6 homozygous patients was significantly higher than that of the patients carrying the normal allele (median, 1.43 and 0.82 μg/mL, respectively,
p
= 0.0054). The *6 and *28 heterozygous patients also showed significantly higher values than those shown by patients with the normal allele. Multivariate analysis revealed that carrying one or two
UGT1A1
*6 gene polymorphisms, one
UGT1A1
*28 polymorphism, and age of < 40 years were independent factors associated with high DTG trough concentrations. The median DTG trough concentration was significantly higher in the patients with NP-AEs (1.31 μg/mL) than in those without NP-AEs (1.01 μg/mL). Consistent with these results, subjects carrying
UGT1A1
*6,
UGT1A1
*28, or both alleles showed a higher cumulative incidence of having selected NP-AEs than those carrying the normal alleles (
p
= 0.0454).
Conclusion
In addition to younger age, carrying
UGT1A1
*6 and/or
UGT1A1
*28 was demonstrated to be a factor associated with high DTG trough concentrations. Our results also suggest a relationship between plasma DTG trough concentrations and NP-AEs, and that carrying
UGT1A1
*6 and/or
UGT1A1
*28 alleles might be a risk factor for NP-AEs. |
|---|---|
| AbstractList | Dolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450 3A (CYP3A). Therefore, we focused on UGT1A1 gene polymorphisms (*6 and *28) in Japanese individuals infected with human immunodeficiency virus (HIV)-1 to examine the relationship between their plasma trough concentration of DTG and gene polymorphisms. Recently, neuropsychiatric adverse events (NP-AEs) after the use of DTG have become a concern, so the association between UGT1A1 gene polymorphisms and selected NP-AEs was also investigated. The study subjects were 107 Japanese patients with HIV-1 infections who were receiving DTG. Five symptoms (dizziness, headache, insomnia, restlessness, and anxiety) were selected as NP-AEs. The subjects were classified by their UGT1A1 gene polymorphisms for the group comparison of DTG trough concentration and the presence or absence of NP-AEs. The subjects consisted of eight (7%) *6 homozygotes, three (3%) *28 homozygotes, four (4%) for *6/*28 compound heterozygotes, 23 (21%) *6 heterozygotes, 18 (17%) *28 heterozygotes, and 51 (48%) patients carrying the normal allele. The plasma DTG trough concentration of the *6 homozygous patients was significantly higher than that of the patients carrying the normal allele (median, 1.43 and 0.82 [mu]g/mL, respectively, p = 0.0054). The *6 and *28 heterozygous patients also showed significantly higher values than those shown by patients with the normal allele. Multivariate analysis revealed that carrying one or two UGT1A1*6 gene polymorphisms, one UGT1A1*28 polymorphism, and age of < 40 years were independent factors associated with high DTG trough concentrations. The median DTG trough concentration was significantly higher in the patients with NP-AEs (1.31 [mu]g/mL) than in those without NP-AEs (1.01 [mu]g/mL). Consistent with these results, subjects carrying UGT1A1*6, UGT1A1*28, or both alleles showed a higher cumulative incidence of having selected NP-AEs than those carrying the normal alleles (p = 0.0454). In addition to younger age, carrying UGT1A1*6 and/or UGT1A1*28 was demonstrated to be a factor associated with high DTG trough concentrations. Our results also suggest a relationship between plasma DTG trough concentrations and NP-AEs, and that carrying UGT1A1*6 and/or UGT1A1*28 alleles might be a risk factor for NP-AEs. Background Dolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450 3A (CYP3A). Therefore, we focused on UGT1A1 gene polymorphisms (*6 and *28) in Japanese individuals infected with human immunodeficiency virus (HIV)-1 to examine the relationship between their plasma trough concentration of DTG and gene polymorphisms. Recently, neuropsychiatric adverse events (NP-AEs) after the use of DTG have become a concern, so the association between UGT1A1 gene polymorphisms and selected NP-AEs was also investigated. Methods The study subjects were 107 Japanese patients with HIV-1 infections who were receiving DTG. Five symptoms (dizziness, headache, insomnia, restlessness, and anxiety) were selected as NP-AEs. The subjects were classified by their UGT1A1 gene polymorphisms for the group comparison of DTG trough concentration and the presence or absence of NP-AEs. Results The subjects consisted of eight (7%) *6 homozygotes, three (3%) * 28 homozygotes, four (4%) for *6/ * 28 compound heterozygotes, 23 (21%) *6 heterozygotes, 18 (17%) * 28 heterozygotes, and 51 (48%) patients carrying the normal allele. The plasma DTG trough concentration of the *6 homozygous patients was significantly higher than that of the patients carrying the normal allele (median, 1.43 and 0.82 μg/mL, respectively, p = 0.0054). The *6 and *28 heterozygous patients also showed significantly higher values than those shown by patients with the normal allele. Multivariate analysis revealed that carrying one or two UGT1A1 *6 gene polymorphisms, one UGT1A1 *28 polymorphism, and age of < 40 years were independent factors associated with high DTG trough concentrations. The median DTG trough concentration was significantly higher in the patients with NP-AEs (1.31 μg/mL) than in those without NP-AEs (1.01 μg/mL). Consistent with these results, subjects carrying UGT1A1 *6, UGT1A1 *28, or both alleles showed a higher cumulative incidence of having selected NP-AEs than those carrying the normal alleles ( p = 0.0454). Conclusion In addition to younger age, carrying UGT1A1 *6 and/or UGT1A1 *28 was demonstrated to be a factor associated with high DTG trough concentrations. Our results also suggest a relationship between plasma DTG trough concentrations and NP-AEs, and that carrying UGT1A1 *6 and/or UGT1A1 *28 alleles might be a risk factor for NP-AEs. Dolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450 3A (CYP3A). Therefore, we focused on UGT1A1 gene polymorphisms (*6 and *28) in Japanese individuals infected with human immunodeficiency virus (HIV)-1 to examine the relationship between their plasma trough concentration of DTG and gene polymorphisms. Recently, neuropsychiatric adverse events (NP-AEs) after the use of DTG have become a concern, so the association between UGT1A1 gene polymorphisms and selected NP-AEs was also investigated. The study subjects were 107 Japanese patients with HIV-1 infections who were receiving DTG. Five symptoms (dizziness, headache, insomnia, restlessness, and anxiety) were selected as NP-AEs. The subjects were classified by their UGT1A1 gene polymorphisms for the group comparison of DTG trough concentration and the presence or absence of NP-AEs. The subjects consisted of eight (7%) *6 homozygotes, three (3%) *28 homozygotes, four (4%) for *6/*28 compound heterozygotes, 23 (21%) *6 heterozygotes, 18 (17%) *28 heterozygotes, and 51 (48%) patients carrying the normal allele. The plasma DTG trough concentration of the *6 homozygous patients was significantly higher than that of the patients carrying the normal allele (median, 1.43 and 0.82 μg/mL, respectively, p = 0.0054). The *6 and *28 heterozygous patients also showed significantly higher values than those shown by patients with the normal allele. Multivariate analysis revealed that carrying one or two UGT1A1*6 gene polymorphisms, one UGT1A1*28 polymorphism, and age of < 40 years were independent factors associated with high DTG trough concentrations. The median DTG trough concentration was significantly higher in the patients with NP-AEs (1.31 μg/mL) than in those without NP-AEs (1.01 μg/mL). Consistent with these results, subjects carrying UGT1A1*6, UGT1A1*28, or both alleles showed a higher cumulative incidence of having selected NP-AEs than those carrying the normal alleles (p = 0.0454). In addition to younger age, carrying UGT1A1*6 and/or UGT1A1*28 was demonstrated to be a factor associated with high DTG trough concentrations. Our results also suggest a relationship between plasma DTG trough concentrations and NP-AEs, and that carrying UGT1A1*6 and/or UGT1A1*28 alleles might be a risk factor for NP-AEs. Background Dolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450 3A (CYP3A). Therefore, we focused on UGT1A1 gene polymorphisms (*6 and *28) in Japanese individuals infected with human immunodeficiency virus (HIV)-1 to examine the relationship between their plasma trough concentration of DTG and gene polymorphisms. Recently, neuropsychiatric adverse events (NP-AEs) after the use of DTG have become a concern, so the association between UGT1A1 gene polymorphisms and selected NP-AEs was also investigated. Methods The study subjects were 107 Japanese patients with HIV-1 infections who were receiving DTG. Five symptoms (dizziness, headache, insomnia, restlessness, and anxiety) were selected as NP-AEs. The subjects were classified by their UGT1A1 gene polymorphisms for the group comparison of DTG trough concentration and the presence or absence of NP-AEs. Results The subjects consisted of eight (7%) *6 homozygotes, three (3%) *28 homozygotes, four (4%) for *6/*28 compound heterozygotes, 23 (21%) *6 heterozygotes, 18 (17%) *28 heterozygotes, and 51 (48%) patients carrying the normal allele. The plasma DTG trough concentration of the *6 homozygous patients was significantly higher than that of the patients carrying the normal allele (median, 1.43 and 0.82 [mu]g/mL, respectively, p = 0.0054). The *6 and *28 heterozygous patients also showed significantly higher values than those shown by patients with the normal allele. Multivariate analysis revealed that carrying one or two UGT1A1*6 gene polymorphisms, one UGT1A1*28 polymorphism, and age of < 40 years were independent factors associated with high DTG trough concentrations. The median DTG trough concentration was significantly higher in the patients with NP-AEs (1.31 [mu]g/mL) than in those without NP-AEs (1.01 [mu]g/mL). Consistent with these results, subjects carrying UGT1A1*6, UGT1A1*28, or both alleles showed a higher cumulative incidence of having selected NP-AEs than those carrying the normal alleles (p = 0.0454). Conclusion In addition to younger age, carrying UGT1A1*6 and/or UGT1A1*28 was demonstrated to be a factor associated with high DTG trough concentrations. Our results also suggest a relationship between plasma DTG trough concentrations and NP-AEs, and that carrying UGT1A1*6 and/or UGT1A1*28 alleles might be a risk factor for NP-AEs. Keywords: Dolutegravir, Plasma trough concentration, UGT1A1 gene polymorphism, Neuropsychiatric adverse events Abstract Background Dolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450 3A (CYP3A). Therefore, we focused on UGT1A1 gene polymorphisms (*6 and *28) in Japanese individuals infected with human immunodeficiency virus (HIV)-1 to examine the relationship between their plasma trough concentration of DTG and gene polymorphisms. Recently, neuropsychiatric adverse events (NP-AEs) after the use of DTG have become a concern, so the association between UGT1A1 gene polymorphisms and selected NP-AEs was also investigated. Methods The study subjects were 107 Japanese patients with HIV-1 infections who were receiving DTG. Five symptoms (dizziness, headache, insomnia, restlessness, and anxiety) were selected as NP-AEs. The subjects were classified by their UGT1A1 gene polymorphisms for the group comparison of DTG trough concentration and the presence or absence of NP-AEs. Results The subjects consisted of eight (7%) *6 homozygotes, three (3%) *28 homozygotes, four (4%) for *6/*28 compound heterozygotes, 23 (21%) *6 heterozygotes, 18 (17%) *28 heterozygotes, and 51 (48%) patients carrying the normal allele. The plasma DTG trough concentration of the *6 homozygous patients was significantly higher than that of the patients carrying the normal allele (median, 1.43 and 0.82 μg/mL, respectively, p = 0.0054). The *6 and *28 heterozygous patients also showed significantly higher values than those shown by patients with the normal allele. Multivariate analysis revealed that carrying one or two UGT1A1*6 gene polymorphisms, one UGT1A1*28 polymorphism, and age of < 40 years were independent factors associated with high DTG trough concentrations. The median DTG trough concentration was significantly higher in the patients with NP-AEs (1.31 μg/mL) than in those without NP-AEs (1.01 μg/mL). Consistent with these results, subjects carrying UGT1A1*6, UGT1A1*28, or both alleles showed a higher cumulative incidence of having selected NP-AEs than those carrying the normal alleles (p = 0.0454). Conclusion In addition to younger age, carrying UGT1A1*6 and/or UGT1A1*28 was demonstrated to be a factor associated with high DTG trough concentrations. Our results also suggest a relationship between plasma DTG trough concentrations and NP-AEs, and that carrying UGT1A1*6 and/or UGT1A1*28 alleles might be a risk factor for NP-AEs. Background Dolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450 3A (CYP3A). Therefore, we focused on UGT1A1 gene polymorphisms (*6 and *28) in Japanese individuals infected with human immunodeficiency virus (HIV)-1 to examine the relationship between their plasma trough concentration of DTG and gene polymorphisms. Recently, neuropsychiatric adverse events (NP-AEs) after the use of DTG have become a concern, so the association between UGT1A1 gene polymorphisms and selected NP-AEs was also investigated. Methods The study subjects were 107 Japanese patients with HIV-1 infections who were receiving DTG. Five symptoms (dizziness, headache, insomnia, restlessness, and anxiety) were selected as NP-AEs. The subjects were classified by their UGT1A1 gene polymorphisms for the group comparison of DTG trough concentration and the presence or absence of NP-AEs. Results The subjects consisted of eight (7%) *6 homozygotes, three (3%) *28 homozygotes, four (4%) for *6/*28 compound heterozygotes, 23 (21%) *6 heterozygotes, 18 (17%) *28 heterozygotes, and 51 (48%) patients carrying the normal allele. The plasma DTG trough concentration of the *6 homozygous patients was significantly higher than that of the patients carrying the normal allele (median, 1.43 and 0.82 μg/mL, respectively, p = 0.0054). The *6 and *28 heterozygous patients also showed significantly higher values than those shown by patients with the normal allele. Multivariate analysis revealed that carrying one or two UGT1A1*6 gene polymorphisms, one UGT1A1*28 polymorphism, and age of < 40 years were independent factors associated with high DTG trough concentrations. The median DTG trough concentration was significantly higher in the patients with NP-AEs (1.31 μg/mL) than in those without NP-AEs (1.01 μg/mL). Consistent with these results, subjects carrying UGT1A1*6, UGT1A1*28, or both alleles showed a higher cumulative incidence of having selected NP-AEs than those carrying the normal alleles (p = 0.0454). Conclusion In addition to younger age, carrying UGT1A1*6 and/or UGT1A1*28 was demonstrated to be a factor associated with high DTG trough concentrations. Our results also suggest a relationship between plasma DTG trough concentrations and NP-AEs, and that carrying UGT1A1*6 and/or UGT1A1*28 alleles might be a risk factor for NP-AEs. Dolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450 3A (CYP3A). Therefore, we focused on UGT1A1 gene polymorphisms (*6 and *28) in Japanese individuals infected with human immunodeficiency virus (HIV)-1 to examine the relationship between their plasma trough concentration of DTG and gene polymorphisms. Recently, neuropsychiatric adverse events (NP-AEs) after the use of DTG have become a concern, so the association between UGT1A1 gene polymorphisms and selected NP-AEs was also investigated.BACKGROUNDDolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450 3A (CYP3A). Therefore, we focused on UGT1A1 gene polymorphisms (*6 and *28) in Japanese individuals infected with human immunodeficiency virus (HIV)-1 to examine the relationship between their plasma trough concentration of DTG and gene polymorphisms. Recently, neuropsychiatric adverse events (NP-AEs) after the use of DTG have become a concern, so the association between UGT1A1 gene polymorphisms and selected NP-AEs was also investigated.The study subjects were 107 Japanese patients with HIV-1 infections who were receiving DTG. Five symptoms (dizziness, headache, insomnia, restlessness, and anxiety) were selected as NP-AEs. The subjects were classified by their UGT1A1 gene polymorphisms for the group comparison of DTG trough concentration and the presence or absence of NP-AEs.METHODSThe study subjects were 107 Japanese patients with HIV-1 infections who were receiving DTG. Five symptoms (dizziness, headache, insomnia, restlessness, and anxiety) were selected as NP-AEs. The subjects were classified by their UGT1A1 gene polymorphisms for the group comparison of DTG trough concentration and the presence or absence of NP-AEs.The subjects consisted of eight (7%) *6 homozygotes, three (3%) *28 homozygotes, four (4%) for *6/*28 compound heterozygotes, 23 (21%) *6 heterozygotes, 18 (17%) *28 heterozygotes, and 51 (48%) patients carrying the normal allele. The plasma DTG trough concentration of the *6 homozygous patients was significantly higher than that of the patients carrying the normal allele (median, 1.43 and 0.82 μg/mL, respectively, p = 0.0054). The *6 and *28 heterozygous patients also showed significantly higher values than those shown by patients with the normal allele. Multivariate analysis revealed that carrying one or two UGT1A1*6 gene polymorphisms, one UGT1A1*28 polymorphism, and age of < 40 years were independent factors associated with high DTG trough concentrations. The median DTG trough concentration was significantly higher in the patients with NP-AEs (1.31 μg/mL) than in those without NP-AEs (1.01 μg/mL). Consistent with these results, subjects carrying UGT1A1*6, UGT1A1*28, or both alleles showed a higher cumulative incidence of having selected NP-AEs than those carrying the normal alleles (p = 0.0454).RESULTSThe subjects consisted of eight (7%) *6 homozygotes, three (3%) *28 homozygotes, four (4%) for *6/*28 compound heterozygotes, 23 (21%) *6 heterozygotes, 18 (17%) *28 heterozygotes, and 51 (48%) patients carrying the normal allele. The plasma DTG trough concentration of the *6 homozygous patients was significantly higher than that of the patients carrying the normal allele (median, 1.43 and 0.82 μg/mL, respectively, p = 0.0054). The *6 and *28 heterozygous patients also showed significantly higher values than those shown by patients with the normal allele. Multivariate analysis revealed that carrying one or two UGT1A1*6 gene polymorphisms, one UGT1A1*28 polymorphism, and age of < 40 years were independent factors associated with high DTG trough concentrations. The median DTG trough concentration was significantly higher in the patients with NP-AEs (1.31 μg/mL) than in those without NP-AEs (1.01 μg/mL). Consistent with these results, subjects carrying UGT1A1*6, UGT1A1*28, or both alleles showed a higher cumulative incidence of having selected NP-AEs than those carrying the normal alleles (p = 0.0454).In addition to younger age, carrying UGT1A1*6 and/or UGT1A1*28 was demonstrated to be a factor associated with high DTG trough concentrations. Our results also suggest a relationship between plasma DTG trough concentrations and NP-AEs, and that carrying UGT1A1*6 and/or UGT1A1*28 alleles might be a risk factor for NP-AEs.CONCLUSIONIn addition to younger age, carrying UGT1A1*6 and/or UGT1A1*28 was demonstrated to be a factor associated with high DTG trough concentrations. Our results also suggest a relationship between plasma DTG trough concentrations and NP-AEs, and that carrying UGT1A1*6 and/or UGT1A1*28 alleles might be a risk factor for NP-AEs. |
| ArticleNumber | 622 |
| Audience | Academic |
| Author | Yagura, Hiroki Kushida, Hiroyuki Yamazaki, Kunio Kasai, Daisuke Uehira, Tomoko Takahashi, Masaaki Nishida, Yasuharu Shirasaka, Takuma Hirota, Kazuyuki Hirano, Atsushi Ikuma, Motoko Tomishima, Kosuke Watanabe, Dai Yoshino, Munehiro Togami, Hiroaki |
| Author_xml | – sequence: 1 givenname: Hiroki surname: Yagura fullname: Yagura, Hiroki organization: Department of Pharmacy, National Hospital Organization Osaka National Hospital – sequence: 2 givenname: Dai orcidid: 0000-0003-3838-0961 surname: Watanabe fullname: Watanabe, Dai email: dai@onh.go.jp organization: AIDS Medical Center, National Hospital Organization Osaka National Hospital – sequence: 3 givenname: Hiroyuki surname: Kushida fullname: Kushida, Hiroyuki organization: Department of Pharmacy, National Hospital Organization Osaka National Hospital – sequence: 4 givenname: Kosuke surname: Tomishima fullname: Tomishima, Kosuke organization: Department of Pharmacy, National Hospital Organization Osaka National Hospital – sequence: 5 givenname: Hiroaki surname: Togami fullname: Togami, Hiroaki organization: Department of Pharmacy, National Hospital Organization Nagoya Medical Center – sequence: 6 givenname: Atsushi surname: Hirano fullname: Hirano, Atsushi organization: Department of Pharmacy, National Hospital Organization Nagoya Medical Center – sequence: 7 givenname: Masaaki surname: Takahashi fullname: Takahashi, Masaaki organization: Department of Pharmacy, National Hospital Organization Suzuka Hospital – sequence: 8 givenname: Kazuyuki surname: Hirota fullname: Hirota, Kazuyuki organization: AIDS Medical Center, National Hospital Organization Osaka National Hospital – sequence: 9 givenname: Motoko surname: Ikuma fullname: Ikuma, Motoko organization: AIDS Medical Center, National Hospital Organization Osaka National Hospital – sequence: 10 givenname: Daisuke surname: Kasai fullname: Kasai, Daisuke organization: AIDS Medical Center, National Hospital Organization Osaka National Hospital – sequence: 11 givenname: Yasuharu surname: Nishida fullname: Nishida, Yasuharu organization: AIDS Medical Center, National Hospital Organization Osaka National Hospital – sequence: 12 givenname: Munehiro surname: Yoshino fullname: Yoshino, Munehiro organization: Department of Pharmacy, National Hospital Organization Utano Hospital – sequence: 13 givenname: Kunio surname: Yamazaki fullname: Yamazaki, Kunio organization: Department of Pharmacy, National Hospital Organization Osaka National Hospital – sequence: 14 givenname: Tomoko surname: Uehira fullname: Uehira, Tomoko organization: AIDS Medical Center, National Hospital Organization Osaka National Hospital – sequence: 15 givenname: Takuma surname: Shirasaka fullname: Shirasaka, Takuma organization: AIDS Medical Center, National Hospital Organization Osaka National Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28915895$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk81u1DAUhSNURNuBB2CDLLGBRYqdX3uDVFXQDqpUCdpuLcd2Mh4ldrCdYfo2PCp3Oi2aqQAhS4l1_Z3j-MT3ODmwzuokeU3wCSG0-hBIRmuWYlKnWQ2P9bPkiBQ1SbM8Lw525ofJcQhLDCDN2IvkMKOMlJSVR8nP-TAKGZFr0c35NTklqNNWo9H1d4Pz48KEISBn0diLMAikXD9F3XmxMh5F76ZugaSzUtvoRTTOBiSsQlZP3o3hTi6MiN5IJNRK-6CRXgEZkLHoixiF1VAyVpmVUZPoN_VWy6gV-mHiAl3Mb1PyMnnewpJ-9fCeJTefP12fXaSXV-fzs9PLVFY1ialomKY1ZliUBW2oqupSEYgnVyUrWSbzhtYyZzQXkrZYZYSVFDJjNMtpwWibz5L51lc5seSjN4Pwd9wJw-8Lzndc-Ghkr7kuZFvQOitZAQMXVLOsqVlDcFPrCvaaJR-3XuPUDFpt0-n3TPdXrFnwzq14WeEcVxUYvHsw8O77pEPkgwlS9z1E5qbACSswrjCG88ySt0_QpZu8hag2VIlZTfAO1Qk4AMTsYF-5MeWnwBBMyqwE6uQPFAylBwO_WbcG6nuC93sCYKJex05MIfD5t6__z17d7rNvdgP8ndzjvQWg3gLSuxC8brk08f4CwhebnhPMNx3Ctx3C4eLzTYfwNSjJE-Wj-b802VYTgLWd9jsZ_1X0C2JMIWA |
| CitedBy_id | crossref_primary_10_3390_ph15121533 crossref_primary_10_1016_S2352_3018_23_00081_4 crossref_primary_10_1080_14787210_2023_2203914 crossref_primary_10_2217_pgs_2021_0062 crossref_primary_10_1093_jac_dkz217 crossref_primary_10_1093_cid_ciy426 crossref_primary_10_1124_dmd_118_085035 crossref_primary_10_56919_usci_2324_003 crossref_primary_10_1097_QAD_0000000000002029 crossref_primary_10_1177_03331024221088994 crossref_primary_10_1097_QAI_0000000000002608 crossref_primary_10_1016_j_pharmthera_2023_108459 crossref_primary_10_1124_jpet_119_264424 crossref_primary_10_2217_pgs_2023_0105 crossref_primary_10_3390_metabo12121202 crossref_primary_10_5937_mp75_44892 crossref_primary_10_1111_hiv_12710 crossref_primary_10_3389_fphar_2023_1118580 crossref_primary_10_1038_s41397_019_0135_8 crossref_primary_10_2147_IDR_S419308 crossref_primary_10_1016_j_jiac_2019_08_012 crossref_primary_10_1089_aid_2022_0185 crossref_primary_10_1016_S2352_3018_24_00209_1 crossref_primary_10_1186_s40360_023_00715_5 crossref_primary_10_1093_jac_dkab365 crossref_primary_10_1093_jac_dkz572 crossref_primary_10_1080_17512433_2024_2308664 crossref_primary_10_3390_v14051028 crossref_primary_10_1089_omi_2021_0199 crossref_primary_10_1097_FTD_0000000000000618 crossref_primary_10_2217_pgs_2019_0046 crossref_primary_10_1093_jac_dkac290 crossref_primary_10_1002_cpdd_996 crossref_primary_10_1093_jac_dky508 crossref_primary_10_1007_s13365_020_00874_9 crossref_primary_10_1093_cid_ciz853 crossref_primary_10_1016_j_ijantimicag_2022_106697 crossref_primary_10_1002_phar_2246 crossref_primary_10_1093_jac_dkz558 crossref_primary_10_1007_s40262_020_00916_9 crossref_primary_10_1080_00498254_2025_2453983 crossref_primary_10_1002_psp4_13244 crossref_primary_10_2174_0113892002255240231117072211 crossref_primary_10_1016_S2352_4642_23_00164_5 crossref_primary_10_1093_infdis_jiac174 crossref_primary_10_1097_QAD_0000000000003576 crossref_primary_10_3390_jcm13237031 crossref_primary_10_1007_s40261_018_0739_9 crossref_primary_10_1007_s43440_023_00515_y crossref_primary_10_1111_hiv_13146 crossref_primary_10_1080_17425255_2021_1915285 crossref_primary_10_1128_aac_00430_23 crossref_primary_10_1080_07853890_2018_1561724 crossref_primary_10_1097_FTD_0000000000000684 crossref_primary_10_1111_bcp_14832 crossref_primary_10_1146_annurev_pharmtox_021320_111248 crossref_primary_10_1038_s41397_022_00293_5 crossref_primary_10_1080_17425255_2023_2267970 crossref_primary_10_1007_s00228_022_03367_2 crossref_primary_10_1186_s12977_022_00608_1 crossref_primary_10_1093_infdis_jiaf098 crossref_primary_10_1089_apc_2021_0089 crossref_primary_10_1080_14622416_2024_2441104 crossref_primary_10_1080_17512433_2019_1553615 crossref_primary_10_1128_spectrum_05079_22 crossref_primary_10_1155_2020_9708913 crossref_primary_10_3390_pharmaceutics15041212 |
| Cites_doi | 10.1016/S2352-3018(15)00027-2 10.1016/S1473-3099(13)70257-3 10.1111/j.1365-2125.1985.tb05040.x 10.1097/QAI.0000000000000790 10.1097/QAI.0000000000001269 10.1248/bpb.31.1601 10.1373/clinchem.2011.165613 10.1124/dmd.104.001800 10.2217/pgs.13.190 10.1097/QAD.0000000000001279 10.1111/hiv.12468 10.1128/AAC.00292-13 10.1097/QAD.0000000000001459 10.1097/00002030-200101050-00011 10.1038/sj.tpj.6500335 10.1007/s40262-016-0456-6 10.1097/QAD.0000000000001394 10.2147/DDDT.S84850 10.1097/QAD.0000000000001351 10.1056/NEJMoa1215541 10.1111/bcp.12639 10.1128/AAC.01209-10 10.1097/QAI.0000000000000893 10.1016/j.jiac.2015.06.008 10.1111/j.1532-5415.1979.tb01715.x |
| ContentType | Journal Article |
| Copyright | The Author(s). 2017 COPYRIGHT 2017 BioMed Central Ltd. Copyright BioMed Central 2017 |
| Copyright_xml | – notice: The Author(s). 2017 – notice: COPYRIGHT 2017 BioMed Central Ltd. – notice: Copyright BioMed Central 2017 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QL 7T2 7U9 7X7 7XB 88E 8C1 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12879-017-2717-x |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Health and Safety Science Abstracts (Full archive) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts Health & Safety Science Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2334 |
| EndPage | 8 |
| ExternalDocumentID | oai_doaj_org_article_e4cf4872594949048e92b79b10b7e62c PMC5603066 A509101525 28915895 10_1186_s12879_017_2717_x |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Japan Agency for Medical Research and Development (AMED) grantid: Research Program on HIV/AIDS – fundername: ; grantid: Research Program on HIV/AIDS |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8C1 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR IOV ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX ALIPV CITATION -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7QL 7T2 7U9 7XB 8FK AHSBF AZQEC C1K DWQXO H94 K9. M7N PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c671t-ab9e87090a548b8d675d11283d59592c3b87c3983ac8f0d2195827198238498f3 |
| IEDL.DBID | 8C1 |
| ISSN | 1471-2334 |
| IngestDate | Wed Aug 27 01:19:56 EDT 2025 Thu Aug 21 13:38:10 EDT 2025 Fri Sep 05 05:23:54 EDT 2025 Fri Jul 25 08:42:46 EDT 2025 Tue Jun 17 21:29:55 EDT 2025 Tue Jun 10 20:36:02 EDT 2025 Fri Jun 27 05:02:22 EDT 2025 Fri Jun 27 04:08:55 EDT 2025 Wed Feb 19 02:44:21 EST 2025 Thu Apr 24 23:01:36 EDT 2025 Tue Jul 01 01:57:27 EDT 2025 Sat Sep 06 07:29:56 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Plasma trough concentration gene polymorphism Neuropsychiatric adverse events Dolutegravir UGT1A1 gene polymorphism |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c671t-ab9e87090a548b8d675d11283d59592c3b87c3983ac8f0d2195827198238498f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-3838-0961 |
| OpenAccessLink | https://www.proquest.com/docview/1945097108?pq-origsite=%requestingapplication% |
| PMID | 28915895 |
| PQID | 1945097108 |
| PQPubID | 42582 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_e4cf4872594949048e92b79b10b7e62c pubmedcentral_primary_oai_pubmedcentral_nih_gov_5603066 proquest_miscellaneous_1940060098 proquest_journals_1945097108 gale_infotracmisc_A509101525 gale_infotracacademiconefile_A509101525 gale_incontextgauss_ISR_A509101525 gale_incontextgauss_IOV_A509101525 pubmed_primary_28915895 crossref_citationtrail_10_1186_s12879_017_2717_x crossref_primary_10_1186_s12879_017_2717_x springer_journals_10_1186_s12879_017_2717_x |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-09-16 |
| PublicationDateYYYYMMDD | 2017-09-16 |
| PublicationDate_xml | – month: 09 year: 2017 text: 2017-09-16 day: 16 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationSubtitle | BMC series – open, inclusive and trusted |
| PublicationTitle | BMC infectious diseases |
| PublicationTitleAbbrev | BMC Infect Dis |
| PublicationTitleAlternate | BMC Infect Dis |
| PublicationYear | 2017 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | J Zhang (2717_CR8) 2015; 80 K Tsuchiya (2717_CR28) 2016; 72 M Saeki (2717_CR12) 2006; 6 C Hoffmann (2717_CR15) 2017; 18 M Kobayashi (2717_CR24) 2011; 55 P Bonfanti (2717_CR16) 2017; 31 SL Walmsley (2717_CR1) 2013; 369 S Walmsley (2717_CR4) 2015; 70 2717_CR5 2717_CR6 JM Molina (2717_CR2) 2015; 2 C Marzolini (2717_CR27) 2001; 15 A Fettiplace (2717_CR19) 2017; 74 H Yagura (2717_CR21) 2015; 21 DJ Greenblatt (2717_CR26) 1979; 27 A Calcagno (2717_CR9) 2017; 56 N Kaniwa (2717_CR10) 2005; 33 MG Boer de (2717_CR14) 2016; 30 CG Swift (2717_CR25) 1985; 20 A Menard (2717_CR20) 2017; 31 Y Ando (2717_CR11) 2007; 9 S Chen (2717_CR13) 2014; 15 M Takahashi (2717_CR22) 2008; 31 S Castellino (2717_CR23) 2013; 57 C Briand (2717_CR17) 2017; 72 F Raffi (2717_CR3) 2013; 13 L Elens (2717_CR29) 2011; 57 D Cattaneo (2717_CR18) 2017; 31 CE Kandel (2717_CR7) 2015; 9 26185421 - Drug Des Devel Ther. 2015 Jul 07;9:3547-55 27860104 - HIV Med. 2017 Jan;18(1):56-63 18670096 - Biol Pharm Bull. 2008 Aug;31(8):1601-4 21115794 - Antimicrob Agents Chemother. 2011 Feb;55(2):813-21 28272138 - AIDS. 2017 Mar 27;31(6):867-868 24074642 - Lancet Infect Dis. 2013 Nov;13(11):927-35 23669385 - Antimicrob Agents Chemother. 2013 Aug;57(8):3536-46 27824625 - AIDS. 2016 Nov 28;30(18):2831-2834 11192870 - AIDS. 2001 Jan 5;15(1):71-5 25819132 - Br J Clin Pharmacol. 2015 Sep;80(3):502-14 27984559 - J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):423-431 27999017 - J Antimicrob Chemother. 2017 Mar 1;72 (3):837-843 26262777 - J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):515-9 28441180 - AIDS. 2017 May 15;31(8):1201-1203 24195548 - N Engl J Med. 2013 Nov 7;369(19):1807-18 21903774 - Clin Chem. 2011 Nov;57(11):1574-83 26424673 - Lancet HIV. 2015 Apr;2(4):e127-36 17608024 - Curr Opin Mol Ther. 2007 Jun;9(3):258-62 15572581 - Drug Metab Dispos. 2005 Mar;33(3):458-65 24329186 - Pharmacogenomics. 2014 Jan;15(1):9-16 27097364 - J Acquir Immune Defic Syndr. 2016 May 1;72 (1):11-4 27641153 - Clin Pharmacokinet. 2017 Apr;56(4):355-369 26233886 - J Infect Chemother. 2015 Oct;21(10):713-7 759470 - J Am Geriatr Soc. 1979 Jan;27(1):20-2 28079544 - AIDS. 2017 Jan 28;31(3):455-457 3929807 - Br J Clin Pharmacol. 1985 Aug;20(2):111-8 16314888 - Pharmacogenomics J. 2006 Jan-Feb;6(1):63-75 |
| References_xml | – volume: 2 start-page: e127 year: 2015 ident: 2717_CR2 publication-title: Lancet HIV doi: 10.1016/S2352-3018(15)00027-2 – volume: 13 start-page: 927 year: 2013 ident: 2717_CR3 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(13)70257-3 – volume: 20 start-page: 111 year: 1985 ident: 2717_CR25 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1985.tb05040.x – volume: 9 start-page: 258 year: 2007 ident: 2717_CR11 publication-title: Curr Opin Mol Ther – volume: 70 start-page: 515 year: 2015 ident: 2717_CR4 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0000000000000790 – ident: 2717_CR5 – volume: 74 start-page: 423 year: 2017 ident: 2717_CR19 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0000000000001269 – volume: 31 start-page: 1601 year: 2008 ident: 2717_CR22 publication-title: Biol Pharm Bull doi: 10.1248/bpb.31.1601 – volume: 57 start-page: 1574 year: 2011 ident: 2717_CR29 publication-title: Clin Chem doi: 10.1373/clinchem.2011.165613 – volume: 33 start-page: 458 year: 2005 ident: 2717_CR10 publication-title: Drug Metab Dispos doi: 10.1124/dmd.104.001800 – volume: 15 start-page: 9 year: 2014 ident: 2717_CR13 publication-title: Pharmacogenomics doi: 10.2217/pgs.13.190 – volume: 30 start-page: 2831 year: 2016 ident: 2717_CR14 publication-title: AIDS doi: 10.1097/QAD.0000000000001279 – volume: 18 start-page: 56 year: 2017 ident: 2717_CR15 publication-title: HIV Med doi: 10.1111/hiv.12468 – volume: 57 start-page: 3536 year: 2013 ident: 2717_CR23 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00292-13 – volume: 31 start-page: 1201 year: 2017 ident: 2717_CR20 publication-title: AIDS doi: 10.1097/QAD.0000000000001459 – volume: 72 start-page: 837 year: 2017 ident: 2717_CR17 publication-title: J Antimicrob Chemother – volume: 15 start-page: 71 year: 2001 ident: 2717_CR27 publication-title: AIDS doi: 10.1097/00002030-200101050-00011 – volume: 6 start-page: 63 year: 2006 ident: 2717_CR12 publication-title: Pharmacogenomics J doi: 10.1038/sj.tpj.6500335 – volume: 56 start-page: 355 year: 2017 ident: 2717_CR9 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-016-0456-6 – ident: 2717_CR6 – volume: 31 start-page: 867 year: 2017 ident: 2717_CR18 publication-title: AIDS doi: 10.1097/QAD.0000000000001394 – volume: 9 start-page: 3547 year: 2015 ident: 2717_CR7 publication-title: Drug Des Devel Ther doi: 10.2147/DDDT.S84850 – volume: 31 start-page: 455 year: 2017 ident: 2717_CR16 publication-title: AIDS doi: 10.1097/QAD.0000000000001351 – volume: 369 start-page: 1807 year: 2013 ident: 2717_CR1 publication-title: N Engl J Med doi: 10.1056/NEJMoa1215541 – volume: 80 start-page: 502 year: 2015 ident: 2717_CR8 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.12639 – volume: 55 start-page: 813 year: 2011 ident: 2717_CR24 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01209-10 – volume: 72 start-page: 11 year: 2016 ident: 2717_CR28 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0000000000000893 – volume: 21 start-page: 713 year: 2015 ident: 2717_CR21 publication-title: J Infect Chemother doi: 10.1016/j.jiac.2015.06.008 – volume: 27 start-page: 20 year: 1979 ident: 2717_CR26 publication-title: J Am Geriatr Soc doi: 10.1111/j.1532-5415.1979.tb01715.x – reference: 26233886 - J Infect Chemother. 2015 Oct;21(10):713-7 – reference: 28272138 - AIDS. 2017 Mar 27;31(6):867-868 – reference: 26185421 - Drug Des Devel Ther. 2015 Jul 07;9:3547-55 – reference: 27860104 - HIV Med. 2017 Jan;18(1):56-63 – reference: 23669385 - Antimicrob Agents Chemother. 2013 Aug;57(8):3536-46 – reference: 27984559 - J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):423-431 – reference: 25819132 - Br J Clin Pharmacol. 2015 Sep;80(3):502-14 – reference: 11192870 - AIDS. 2001 Jan 5;15(1):71-5 – reference: 28079544 - AIDS. 2017 Jan 28;31(3):455-457 – reference: 21115794 - Antimicrob Agents Chemother. 2011 Feb;55(2):813-21 – reference: 15572581 - Drug Metab Dispos. 2005 Mar;33(3):458-65 – reference: 28441180 - AIDS. 2017 May 15;31(8):1201-1203 – reference: 26262777 - J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):515-9 – reference: 759470 - J Am Geriatr Soc. 1979 Jan;27(1):20-2 – reference: 24195548 - N Engl J Med. 2013 Nov 7;369(19):1807-18 – reference: 3929807 - Br J Clin Pharmacol. 1985 Aug;20(2):111-8 – reference: 26424673 - Lancet HIV. 2015 Apr;2(4):e127-36 – reference: 21903774 - Clin Chem. 2011 Nov;57(11):1574-83 – reference: 17608024 - Curr Opin Mol Ther. 2007 Jun;9(3):258-62 – reference: 27097364 - J Acquir Immune Defic Syndr. 2016 May 1;72 (1):11-4 – reference: 27824625 - AIDS. 2016 Nov 28;30(18):2831-2834 – reference: 24329186 - Pharmacogenomics. 2014 Jan;15(1):9-16 – reference: 16314888 - Pharmacogenomics J. 2006 Jan-Feb;6(1):63-75 – reference: 24074642 - Lancet Infect Dis. 2013 Nov;13(11):927-35 – reference: 27999017 - J Antimicrob Chemother. 2017 Mar 1;72 (3):837-843 – reference: 27641153 - Clin Pharmacokinet. 2017 Apr;56(4):355-369 – reference: 18670096 - Biol Pharm Bull. 2008 Aug;31(8):1601-4 |
| SSID | ssj0017829 |
| Score | 2.4504042 |
| Snippet | Background
Dolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450 3A... Dolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450 3A (CYP3A).... Background Dolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450 3A... Abstract Background Dolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 622 |
| SubjectTerms | Acquired immune deficiency syndrome Adult AIDS Alleles Analysis Antiretroviral drugs Anxiety Anxiety - chemically induced Anxiety - genetics Asian Continental Ancestry Group - genetics Clinical trials Complications and side effects Cytochrome Cytochrome P450 Dizziness - chemically induced Dizziness - genetics Dolutegravir Dosage and administration Drug therapy Female Gene Frequency Gene polymorphism Genetic aspects Genetic polymorphisms Glucuronosyltransferase Glucuronosyltransferase - genetics Headache Health aspects Heterocyclic Compounds, 3-Ring - adverse effects Heterocyclic Compounds, 3-Ring - blood Heterozygotes HIV HIV and co-infections HIV Infections - drug therapy HIV Infections - genetics HIV Integrase Inhibitors - adverse effects HIV Integrase Inhibitors - blood HIV-1 - pathogenicity Homozygotes Human immunodeficiency virus Humans Infection Infectious Diseases Insomnia Internal Medicine Male Medical Microbiology Medicine Medicine & Public Health Middle Aged Multivariate analysis Neuropsychiatric adverse events Parasitology Patients Plasma trough concentration Polymorphism Polymorphism, Genetic Research Article Risk factors Sleep disorders Sleep Initiation and Maintenance Disorders - chemically induced Sleep Initiation and Maintenance Disorders - genetics Statistical analysis Tropical Medicine UGT1A1 gene polymorphism Uridine Viruses |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4s1CQQYhIYGiOs7TxwVRdisVJOhWvVl-pURqk1WzW_Xn9Kcy43ijTVHhwjUer7Lznnj8DSHvuEuLTOkssjl-rUo0mBR3LNKVxfHaGdMa7w4ffstni_TgJDvZGvWFPWE9PHDPuD2XmgqSasjSEUcF9M0JrguhY6YLl3OD3pcJtimmwvkBxD0RzjDjMt_rwAsX2BdURBzql-hqFIU8WP-fLnkrJt3sl7xxaOpj0f4Dcj8kkXTav_xDcsc1j8jdw3BM_phcz_3dR9pWdPH1KJ7GFNTE0WV7BpU-MLbuzjvaNnQJqfO5ohbVD0EjLusLuvJze6jB64xNwNTtqGos9dCXQ3d0bajCYc6dox4EqqN1Qw8g9OJIS1oP97zwObaMOEvxmy-dzY-j-AlZ7H85-jyLwiiGyORFvIqUFg4sWzAFFY4uLZQZFjK1MrGZyAQ3IOPCJKJMlCkrZjlC2ACnBci7TEVZJU_JTtM27jmhwvFMpdziCVAqYGflKsutFokA55vmE8I2opEm4JTjuIwz6euVMpe9NCVIU6I05dWEfBi2LHuQjr8Rf0J5D4SIr-0fgNbJoHXyX1o3IW9RWyQiaDTYonOq1l0n59-P5dSnYDhW6jainz9GRO8DUdXC3zQqXIsAZiEy14hyd0QJfsCMlzeaK4Mf6mQs0gxRwlg5IW-GZdyJvXWNa9eeBlF5mACaZ72iD8yBcjzOSgE_XoxMYMS98UpT__Io5ZBKQzkK4vy4MZat17pNOC_-h3BeknscTR0HfeS7ZGd1sXavIHVc6dfeS_wGuM9o-g priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal: Open Access Journals [open access] dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3rb9MwELemISG-IMazMJBBSEigQOK87A8IFcRoJxUkWKd9s_zKiNQlXdOi8d_wp3LnpmEZ277G56q5h-8ud_4dIS-ZS_JU6TSwGX6tijWYFHNhoAuL47XTUGu8Ozz5mo2myf5RerRFNuOtWgY2l6Z2OE9qupi9PTv9_QEM_r03eJ69a-CMzbHrJw8YZCcBhJQ3wDFlmItNkn9FBXCGoi1sXrqt55o8gv__5_Q5R3WxifJCJdU7qL075HYbWdLhWhV2yJar7pKbk7Z2fo_8GfsLkbQu6PTLQTSMKOiOo_N6Buk_cLtsThpaV3QO8fSJohZ1EpEkfpULuvTDfKjBO45VC7TbUFVZ6vEwu5bp0lCFE54bRz0yVEPLiu6DP8Y5l7TsLn_hc-wjcZbih2A6Gh8G0X0y3ft88GkUtPMZApPl0TJQWjgwdxEqSHs0t5B7WAjfeGxTkQpmQPC5iQWPleFFaBni2gCnBSgBTwQv4gdku6or94hQ4ViqEmaxLJQI2Fm4wjKrRSzgRE6yAQk3opGmBS_HGRoz6ZMYnsm1NCVIU6I05dmAvO62zNfIHdcRf0R5d4QIuu0f1Itj2dqwdIkpIL-DhBEhfeDoc4LpXOgo1LnLmBmQF6gtEmE1KuzbOVarppHjb4dy6OMynDV1FdGP7z2iVy1RUcNrGtXelQBmIVxXj3K3RwmHg-kvbzRXbmxLRiJJETos5APyvFvGndhwV7l65WkQqicUQPNwregdcyBHj1Iu4Mfzngn0uNdfqcqfHroc4mvIUUGcbzbGcu5vXSWcx9e_xBNyi6ER41yPbJdsLxcr9xQixaV-5u3_L1nJZKQ priority: 102 providerName: Scholars Portal – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9RAEF-kgvgifntaZRVBUILJJtnsPp7F2itUQXulb8t-pQba5GjuxD_HP9WZvb1wqVbwNTsb7nY-diYz8xtCXjNfVKU2ZeI4fq3KDagU82liaofjtcvUGOwdPvrMD-bF4Wl5GsGisRdmO3-fCf6-B_tZYUVPlTCIPBJwF2-WWc5DXpbvDQkDuOhkTFr-ddvo2gno_H_a4K1L6GqB5JUsabh89u-SO9FrpNM1m--RG769T24dxbz4A_JrFpodaVfT-afjbJpRkAtPF905hPZwkk1_0dOupQvwlS80dShviBLxo7mkyzCoh1rsX2wjiG5PdetowLocyqEbSzVOb-49DahPPW1aegh3Lc6wpM3Q2IXPsUbEO4ofeenB7CTJHpL5_sfjvYMkzl5ILK-yZaKN9KDKMtUQ0hjhIK5w4JqJ3JWylMwCUyubS5FrK-rUMcSsgZOWwGBRSFHnj8hO27X-CaHSs1IXzGHKp5Cws_a1Y87IXIK1LfiEpBvWKBuByXE-xrkKAYrgas1NBdxUyE31c0LeDlsWa1SOfxF_QH4PhAioHR6AnKmon8oXtobYDYJBhOsBs-YlM5U0WWoqz5mdkFcoLQohM1qsyTnTq75Xsy8nahp8LpwjdR3Rt68jojeRqO7gb1od-yDgsBCKa0S5O6IExbfj5Y3kqmh4epXJokRYsFRMyMthGXdiMV3ru1WgQRieVALN47WgD4cD8XdWCgkvr0YqMDq98UrbfA-w5OA7Q_wJ7Hy3UZatn3Udc57-F_UzcpuhTuMID75LdpaXK_8cnMKleRHMwW-BKVpq priority: 102 providerName: Springer Nature |
| Title | Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1 |
| URI | https://link.springer.com/article/10.1186/s12879-017-2717-x https://www.ncbi.nlm.nih.gov/pubmed/28915895 https://www.proquest.com/docview/1945097108 https://www.proquest.com/docview/1940060098 https://pubmed.ncbi.nlm.nih.gov/PMC5603066 https://doaj.org/article/e4cf4872594949048e92b79b10b7e62c |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdrC2MvY9_L1gVtDAYbpv629DSS0C4ppBtZU8JehPXhLtDaWZyM_jn7U3enKF7d0b4YbJ2MrdOd7k6n3xHyPjRxluQy8XSK0apIgkiFxvdkobG8duJLiWeHxyfpcBofz5KZC7jVLq1yqxOtotaVwhj5ATjbCeId-ezz4peHVaNwd9WV0NghewHoYBRMNmhSPAJY_bjbyQxYelCDLs4wOyjzQvBivKvWWmQh-_9XzNdWpptZkze2Tu2KdPSIPHSmJO1teP-Y3DPlE3J_7DbLn5I_I3sCklYFnX45DXoBhcli6KK6AH8fhndeX9a0KukCDOjLnGqchAgd8Xu-pCtbvYcqPNRYOmTdmualphYAs8mRniuaY0nn2lALBVXTeUmPYQHGwpZ03pz2wueYOGI0xcgvHY7OvOAZmR4dng6GnivI4Kk0C1ZeLrkB-eZ-Dn6OZBqcDQ32Got0whMeKuB0piLOolyxwtchAtnASHPgOos5K6LnZLesSvOSUG7CJI9DjftAMYeehSl0qCWPOKjgOO0Qf8saoRxaORbNuBDWa2Gp2HBTADcFclNcdcjHpstiA9VxF3Ef-d0QIsq2fVAtz4UTWmFiVYBDBx4iYviArjM8lBmXgS8zk4aqQ97hbBGIo1Fios55vq5rMfp6JnrWEMPiUrcRfZ-0iD44oqKC31S5OxwBg4X4XC3K_RYlaAPVbt7OXOG0US3-yU6HvG2asSdm2JWmWlsaxObxOdC82Ez0ZnDAKQ8SxuHlWUsEWqPXbinnPy1WORjU4JQCOz9theXaZ93GnFd3_8Rr8iBEIcZCHuk-2V0t1-YNmIYr2SU72SzrWi3QJXv9w5NvE7gbpIOuDbbAdRwzuE76P_4Cs85nUw |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEF6VIgEviJtAgQWBkEBW7Y2vfUAoHCVpmyJBUuVt8R4ulho7xAm0_4ZfwG9kZmObuqh966s9u7J3ZufYnfmGkOfM-FGQyMDRIZ5WdSVsKWZcR6Ya22sHrpRYOzzcC_tjf3sSTNbIn7oWBtMqa51oFbUuFJ6Rb0KwHSDekRu_nf1wsGsU3q7WLTRWYrFjjn9ByFa-GXwA_r5gbOvj6H3fqboKOCqMvIWTSG5ASLmbgLMuYw0eswanI-7qgAecKfjcSHV53E1UnLqaIRoLiyA2B-Pm8zjtwryXyGUfT8Zh_0STJsDzwNry6ubUi8PNEmaNMBspcmCCyDlq2T7bIuB_Q3DCEp7O0jx1VWst4NYNcr1yXWlvJWs3yZrJb5Erw-py_jb5PbAVl7RI6fjTyOt5FITT0FlxeDwtgJ1ZOS1pkdMZOOzThGoUeoSq-JnN6cJ2C6IKiyjzCsm3pEmuqQXcbHKyM0UTbCFdGmqhp0qa5XQbDD420qRZU12GzzFRxWiKJ820P9h3vDtkfCGsukvW8yI39wnlhgWJzzTeO_kcRqYm1UxL3uWg8v2wQ9yaNUJV6OjYpONQ2CgpDsWKmwK4KZCb4qhDXjVDZitokPOI3yG_G0JE9bYPivmBqJSEML5KIYCEiBQxg0C3Gs5kxKXnysiETHXIM5QWgbgdOSYGHSTLshSDz_uiZx0_bGZ1FtHXLy2ilxVRWsBvqqQqxoDFQjywFuVGixK0j2q_riVXVNqvFP_2aoc8bV7jSMzoy02xtDSIBeRyoLm3EvRmcVjMvSDmMHnU2gKt1Wu_ybPvFhsdHHgIgoGdr-vNcuKzzmLOg_N_4gm52h8Nd8XuYG_nIbnGcENjE5Fwg6wv5kvzCNzShXxsdQEl3y5a-fwFwZebVQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3rb9MwELfQkCa-IN4UBhiEhASKljhPfyyD0g42EKzTvlnxIyPS5lRNi_hz-FO5c9xoGQyJr_E5an2-V-7ud4S8ZCbJ01Kmgc7wa1UsQaSYCQNZaRyvnYZSYu_wwWE2nSf7J-mJn3PabqrdNynJrqcBUZrsanehq07Ei2y3Ba2aY51PHjCIRwJwIq8naPkwW5vt9WkEMH_cpzL_um1gjBxm_5-a-YJpulw2eSl36kzS5Ba56X1JOu6Yf5tcM_YO2T7w2fK75NfMtUDSpqLzD0fROKJwWwxdNGcQ8MP51u15SxtLF-BBn5dU4y1E7Igf9ZKu3PgeqrCr0Xpo3ZaWVlOHgNkXSdeKljjTuTXUYUG1tLZ0HywwTrakdd_uhc-xcsRoip9-6XR2HET3yHzy_mhvGviJDIHK8mgVlJIbEHAelhDoyEJDtKHBYStinfKUMwWszlXMi7hURRVqhkg2cNIc2F4kvKji-2TLNtY8JJQblpYJ05gISjjsrEylmZY85qCDk2xEwg1rhPJw5Tg140y4sKXIRMdNAdwUyE3xc0Re91sWHVbHv4jfIr97QoTZdg-a5anwUitMoiqI6CBERBAfUHaGM5lzGYUyNxlTI_ICb4tAIA2LlTqn5bptxezzsRg7TwynS11F9O3rgOiVJ6oa-Juq9N0RcFgI0DWg3BlQgjpQw-XNzRVeHbUi4kmKYGFhMSLP-2XciSV21jRrR4PgPCEHmgfdRe8PB6LyKC04vDwfiMDg9IYrtv7uwMrBo4aoFNj5ZiMsF37WVcx59F_Uz8j2l3cT8Wl2-PExucFQvHHGR7ZDtlbLtXkCXuNKPnWa4TdI1mWe |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+UGT1A1+gene+polymorphisms+on+plasma+dolutegravir+trough+concentrations+and+neuropsychiatric+adverse+events+in+Japanese+individuals+infected+with+HIV-1&rft.jtitle=BMC+infectious+diseases&rft.au=Yagura%2C+Hiroki&rft.au=Watanabe%2C+Dai&rft.au=Kushida%2C+Hiroyuki&rft.au=Tomishima%2C+Kosuke&rft.date=2017-09-16&rft.pub=BioMed+Central&rft.eissn=1471-2334&rft.volume=17&rft_id=info:doi/10.1186%2Fs12879-017-2717-x |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon |